ZNF385B

Across TCGA pan-cancer cohorts, ZNF385B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF385B data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ZNF385B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF385B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, COAD, and LUSC are the cancer types where ZNF385B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.109	0.530	<.001	24	view →
COAD	OS	Median	III,IV	0.056	0.783	<.001	12	view →
LUSC	OS	Median	III,IV	0.075	0.674	<.001	6	view →
BLCA	OS	Median	IV	0.193	0.598	.047	3	view →
SKCM	OS	Median	II,III,IV	1.000	0.723	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF385B–ESCA (DFS)

Open the ESCA breakdown →